DEF: Apyx Medical 2026 Proxy: New Incentive Plan & Board Moves

Apyx Medical Corporation has issued its 2026 proxy statement, seeking shareholder approval for a new share incentive plan and the re-election of its board of directors.

Summary

• The 2026 Annual Meeting is scheduled for August 6, 2026, in Uniondale, New York.
• Shareholders will vote on the election of five directors, ratification of RSM US LLP as auditors, an advisory vote on executive compensation, and approval of the 2026 Share Incentive Plan.
• The 2026 Share Incentive Plan proposes to authorize 4,000,000 shares for equity awards.
• Stavros Vizirgianakis was appointed Executive Chairman of the Board effective June 11, 2026.
• The company reported 2025 total revenue of $52.8 million, a 9.9% year-over-year increase, and a reduced operating loss of $6.4 million compared to $18.8 million in 2024.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral-to-positive filing; while the company shows operational improvement and revenue growth, it remains loss-making and is seeking shareholder approval for significant equity dilution via a new incentive plan.

Positives

• Total revenue grew 9.9% year-over-year to $52.8 million.
• Surgical Aesthetics revenue increased 17.4% year-over-year to $45.3 million.
• Operating loss significantly narrowed to $6.4 million from $18.8 million in 2024.
• Successfully received FDA 510(k) clearance for the AYON body contouring system in May 2025.
• Successfully launched Renuvion in China in July 2025.

Negatives

• The company continues to report a net loss, totaling $11.2 million for 2025.
• The company remains dependent on equity-based compensation to attract and retain talent, leading to potential shareholder dilution.
• The company is currently operating in a highly regulated medical device environment, which entails significant compliance costs and risks.

Risks

• The company may not receive FDA clearance for the label expansion of AYON to include power liposuction as anticipated in the second quarter of 2026.
• The company's reliance on a limited number of products (Renuvion and AYON) makes it vulnerable to market shifts or regulatory changes.
• The company may face challenges in maintaining its growth trajectory in the competitive surgical aesthetics market.
• The company's financial performance is subject to risks associated with international operations, including regulatory hurdles in foreign markets.

Future Outlook

The company anticipates receiving FDA clearance for the label expansion of AYON to include power liposuction in the second quarter of 2026 and intends to continue its growth strategy in the surgical aesthetics market.

Management Comments

• The Board believes the 2026 Share Incentive Plan is essential to attract and retain key employees and outside directors.
• The Board believes Stavros Vizirgianakis is best suited for leading discussions regarding performance relative to corporate strategy in his role as Executive Chairman.

Industry Context

StockSavvy.ai notes that Apyx Medical is navigating a competitive surgical aesthetics landscape, focusing on product innovation (AYON) and international expansion (China) to drive growth while managing the transition toward profitability.

Comparison to Industry Standards

• The company's revenue growth of 9.9% is generally consistent with mid-cap medical device companies focusing on niche aesthetic markets.
• The shift toward reducing operating losses is a standard objective for growth-stage medical device firms aiming to reach cash-flow positivity.
• The use of equity-based compensation is standard practice for medical device companies to align management interests with shareholders.

Management Changes

Corporate Governance

Legal Proceedings

• None disclosed.

Related Party Transactions

• Teodora Shileva (spouse of Apyx Bulgaria Managing Director) is an employee in the accounting department.
• Svetoslav Shilev (son of Apyx Bulgaria Managing Director) is a quality manager in the quality assurance department.

Stakeholder Impact

• Shareholders are asked to vote on director elections and a new equity incentive plan that may impact share dilution.
• Employees and directors are eligible for awards under the proposed 2026 Share Incentive Plan.

Next Steps

• Hold the 2026 Annual Meeting of Stockholders on August 6, 2026.
• Seek shareholder approval for the 2026 Share Incentive Plan.
• Continue commercialization efforts for the AYON system.
• Pursue FDA label expansion for AYON.

Key Dates

Recommendation

The company is showing signs of operational improvement and revenue growth, but the ongoing net losses and the request for a new, large share incentive plan suggest a cautious 'hold' approach until the company demonstrates a clearer path to sustained profitability.

Keywords

Apyx Medical, APYX, Proxy Statement, Medical Devices, Renuvion, AYON, Share Incentive Plan, Corporate Governance